Company

Wuhan Huiguan Biotechnology

Wuhan Huiguan Biotechnology develops super-resolution microscopy for in vivo drug screening and disease analysis.

About

Founded in Wuhan in 2022, Wuhan Huiguan Biotechnology develops in vivo drug screening and imaging equipment. Its products include SmartView intelligent light sheet microscopes and the MacroView macroscopic imaging system, which provide biological, structural, and pathological information. The company raised pre-Series A funding in September 2025 led by Hubei Science Technology Investment Group, with Chutian Fengming and Wuhan Optical Valley Financial Holding Group participating. It planned to use the funds for technology development, product commercialization, and R&D team expansion.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in